<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35602902</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2167-8359</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>PeerJ</Title>
          <ISOAbbreviation>PeerJ</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Transcriptome changes in ERGIC3-knockdown hepatocellular carcinoma cells: ERGIC3 is a novel immune function related gene.</ArticleTitle>
        <Pagination>
          <StartPage>e13369</StartPage>
          <MedlinePgn>e13369</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e13369</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.7717/peerj.13369</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">The expression of ERGIC3 is increased in a variety of tumors and promotes the growth and metastasis of liver cancer, but the molecular mechanism needs to be further studied.In this study, we aimed to analyze the molecular mechanism of ERGIC3 regulating the proliferation of human hepatocellular carcinoma (HCC) SMMC-7721 cells using transcriptomics.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="UNASSIGNED">ERGIC3 was knocked down in SMMC-7721 cells by RNAi technique, and the expression of ERGIC3 was detected by Q-RT-PCR and Western Blot. RNA sequencing was performed in the Illumina HiSeq platform in the control group and the ERGIC3i group and bioinformatics methods were selected to analyze the data.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The expression of ERGIC3 was reduced to 10% in SMMC-7721 cells by RNAi technique, and 176 genes were up-regulated and 34 genes were down-regulated in ERGIC3i group compared with the control group. Analysis of the pathways and biological processes that enrich the function of differentially expressed genes showed thatthese differentially expressed genes were mainly involved in vesicular transport, growth factors, PI3K-Akt, NOD-like, Jak-STAT, NF-kappa B and other protein kinase-coupled receptors mediated signal transduction pathways, tumor immune response, collagen-integrin receptor-actin axis, and miRNA pathways. More importantly, most of the significantly altered pathways were related to immunity. ERGIC3 may be a key immune-related gene.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Based on the transcriptomic analysis, the mechanism of ERGIC3 promoting the growth of HCC is link with the transport of growth factor receptor, cytokine receptor and collagen. Then it is involved in signal transduction pathways mediated by protein kinase-coupled receptors, PI3K-Akt, NOD-like, Jak-STAT and NF-kappa B. In particular, the mechanism is also involved in the ERGIC3-dependent immune pathways. ERGIC3 is a potential target for prevention and treatment of HCC.</AbstractText>
          <CopyrightInformation>©2022 Liu et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Liu</LastName>
            <ForeName>Mengyuan</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Zunyi Medical University, Department of Genetics, Guizhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Special Key Laboratory of Oral Disease Research and High Education Institute in Guizhou Province, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Zhao</LastName>
            <ForeName>Qiurong</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Zunyi Medical University, Department of Genetics, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Xiang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Zunyi Medical University, Department of Genetics, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Zunyi Medical University, Department of Genetics, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Yanyu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Zunyi Medical University, Department of Genetics, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xueying</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Zunyi Medical University, Department of Genetics, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Mingsong</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Special Key Laboratory of Oral Disease Research and High Education Institute in Guizhou Province, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>figshare</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>10.6084/m9.figshare.16831558.v1</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>PeerJ</MedlineTA>
        <NlmUniqueID>101603425</NlmUniqueID>
        <ISSNLinking>2167-8359</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cell growth</Keyword>
        <Keyword MajorTopicYN="N">Differentially expressed gene</Keyword>
        <Keyword MajorTopicYN="N">ERGIC3</Keyword>
        <Keyword MajorTopicYN="N">Human hepatocellular carcinoma</Keyword>
        <Keyword MajorTopicYN="N">RNA sequencing</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare there are no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>4</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35602902</ArticleId>
        <ArticleId IdType="pmc">PMC9121864</ArticleId>
        <ArticleId IdType="doi">10.7717/peerj.13369</ArticleId>
        <ArticleId IdType="pii">13369</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Appenzeller-Herzog C, Hauri HP. The ER-Golgi intermediate compartment (ERGIC): in search of its identity and function. Journal of Cell Science. 2006;119:2173–2183. doi: 10.1242/jcs.03019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.03019</ArticleId>
            <ArticleId IdType="pubmed">16723730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68:394–424. doi: 10.3322/caac.21492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21492</ArticleId>
            <ArticleId IdType="pubmed">30207593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brim H, Abu-Asab MS, Nouraie M, Salazar J, De Leo J, Razjouyan H, Mokarram P, Schaffer AA, Naghibhossaini F, Ashktorab H. An integrative CGH, MSI and candidate genes methylation analysis of colorectal tumors. PLOS ONE. 2014;9:e82185.  doi: 10.1371/journal.pone.0082185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0082185</ArticleId>
            <ArticleId IdType="pmc">PMC3903472</ArticleId>
            <ArticleId IdType="pubmed">24475022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA: A Cancer Journal for Clinicians. 2016;66:115–132. doi: 10.3322/caac.21338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21338</ArticleId>
            <ArticleId IdType="pubmed">26808342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, Zheng R, Zhang S, Zeng H, Zuo T, Xia C, Yang Z, He J. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chinese Journal of Cancer Research. 2017;29:1–10. doi: 10.21147/j.issn.1000-9604.2017.01.01.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21147/j.issn.1000-9604.2017.01.01</ArticleId>
            <ArticleId IdType="pmc">PMC5348470</ArticleId>
            <ArticleId IdType="pubmed">28373748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhar D, Antonucci L, Nakagawa H, Kim JY, Glitzner E, Caruso S, Shalapour S, Yang L, Valasek MA, Lee S, Minnich K, Seki E, Tuckermann J, Sibilia M, Zucman-Rossi J, Kari nM. Liver cancer initiation requires p53 inhibition by CD44-enhanced growth factor signaling. Cancer Cell. 2018;33:1061–1077. doi: 10.1016/j.ccell.2018.05.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.05.003</ArticleId>
            <ArticleId IdType="pmc">PMC6005359</ArticleId>
            <ArticleId IdType="pubmed">29894692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao ZQ, Wang JF, Chen DH, Ma XS, Tang Z. Effects of small interfering RNA transfection of B cell lymphoma/leukemia-2-associated athanogene-1 gene on biological characteristics of hepatocellular carcinoma cells. Chinese Journal of Experimental Surgery. 2017;34:1900–1903.</Citation>
        </Reference>
        <Reference>
          <Citation>Hong SH, Chang SH, Cho KC, Kim S, Park S, Lee AY, Jiang HL, Kim HJ, Lee S, Yu KN, Seo HW, Chae C, Kim KP, Park J, Cho MH. Endoplasmic reticulum-Golgi intermediate compartment protein 3 knockdown suppresses lung cancer through endoplasmic reticulum stress-induced autophagy. Oncotarget. 2016;7:65335–65347. doi: 10.18632/oncotarget.11678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.11678</ArticleId>
            <ArticleId IdType="pmc">PMC5323159</ArticleId>
            <ArticleId IdType="pubmed">27588471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howden JD, Michael M, Hight-Warburton W, Parsons M. α2β1 integrins spatially restrict Cdc42 activity to stabilise adherens junctions. BMC Biology. 2021;19:130. doi: 10.1186/s12915-021-01054-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12915-021-01054-9</ArticleId>
            <ArticleId IdType="pmc">PMC8220754</ArticleId>
            <ArticleId IdType="pubmed">34158053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu S, Zhao L, Yang J, Hu M. The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases. Tumour Biology. 2014;35:3647–3656. doi: 10.1007/s13277-013-1483-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13277-013-1483-7</ArticleId>
            <ArticleId IdType="pubmed">24326769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang MW, Lin CD, Chen JF. Integrin activation, Focal adhesion maturation and tumor metastasis. Sheng Li Xue Bao. 2021;73:151–159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33903877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leung Z, Ko FCF, Tey SK, Kwong EML, Mao X, Liu BHM, Ma APY, Fung YME, Che CM, Wong DKH, Lai CL, Ng IO, Yam JWP. Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells. Journal of Experimental &amp; Clinical Cancer Research. 2019;38:423. doi: 10.1186/s13046-019-1402-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-019-1402-x</ArticleId>
            <ArticleId IdType="pmc">PMC6805403</ArticleId>
            <ArticleId IdType="pubmed">31640796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Research. 2020;48:W509–W514. doi: 10.1093/nar/gkaa407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkaa407</ArticleId>
            <ArticleId IdType="pmc">PMC7319575</ArticleId>
            <ArticleId IdType="pubmed">32442275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin QH, Zhang KD, Duan HX, Liu MX, Wei WL, Cao Y. ERGIC3, which is regulated by miR-203a, is a potential biomarker for non-small cell lung cancer. Cancer Science. 2015;106:1463–1473. doi: 10.1111/cas.12741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.12741</ArticleId>
            <ArticleId IdType="pmc">PMC4638005</ArticleId>
            <ArticleId IdType="pubmed">26177443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu C, Xia J, Zhou Y, Lu X, Zhang L, Gou M, Li L, Zhang X, Ji H, Zhu K, Li L, Zhang J, Yu P, Yang J, Bu H, Shi Y. Loss of Gs α impairs liver regeneration through a defect in the crosstalk between cAMP and growth factor signaling. Journal of Hepatology. 2016;64:342–351. doi: 10.1016/j.jhep.2015.08.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2015.08.036</ArticleId>
            <ArticleId IdType="pubmed">26386161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121–124. doi: 10.1126/science.1140485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1140485</ArticleId>
            <ArticleId IdType="pubmed">17615358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishikawa M, Kira Y, Yabunaka Y, Inoue M. Identification and characterization of endoplasmic reticulum-associated protein, ERp43.  Gene. 2007;386:42–51. doi: 10.1016/j.gene.2006.06.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2006.06.030</ArticleId>
            <ArticleId IdType="pubmed">17020792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otte S, Belden WJ, Heidtman M, Liu J, Jensen ON, Barlowe C. Erv41p and Erv46p: new components of COPII vesicles involved in transport between the ER and Golgi complex. Journal of Cell Biology. 2001;152:503–518. doi: 10.1083/jcb.152.3.503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.152.3.503</ArticleId>
            <ArticleId IdType="pmc">PMC2195992</ArticleId>
            <ArticleId IdType="pubmed">11157978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nature Protocols. 2008;3:1101–1108. doi: 10.1038/nprot.2008.73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nprot.2008.73</ArticleId>
            <ArticleId IdType="pubmed">18546601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi G, Wu B, Yan S, Zhang GN, Lan C, Zeng LJ, Li JS. Effect of silencing Gli2 gene on proliferation and apoptosis of the hepatocellular carcinoma SMMC-7721 line cell. Chinese Journal of Cancer Biotherapy. 2017;24:1260–1265.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang X, Sun W, Shen W, Xia M, Chen C, Xiang D, Ning B, Cui X, Li H, Li X, Ding J, Wang H. Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis. Journal of Hepatology. 2016;64:1283–1294. doi: 10.1016/j.jhep.2016.01.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2016.01.019</ArticleId>
            <ArticleId IdType="pubmed">26812074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Welsh LM, Tong AH, Boone C, Jensen ON, Otte S. Genetic and molecular interactions of the Erv41p-Erv46p complex involved in transport between the endoplasmic reticulum and Golgi complex. Journal of Cell Science. 2006;119:4730–4740. doi: 10.1242/jcs.03250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.03250</ArticleId>
            <ArticleId IdType="pubmed">17077122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu M, Tu T, Huang Y, Cao Y. Suppression subtractive hybridization identified differentially expressed genes in lung adenocarcinoma: ERGIC3 as a novel lung cancer-related gene. BMC Cancer. 2013;13:1–11. doi: 10.1186/1471-2407-13-44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-13-44</ArticleId>
            <ArticleId IdType="pmc">PMC3545739</ArticleId>
            <ArticleId IdType="pubmed">23282137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao YC, Yang ZB, Cheng XS, Fang XB, Shen T, Xia CF, Liu P, Qian HH, Sun B, Yin ZF, Li YF. CXCL8, overexpressed in colorectal cancer, enhances the resistance of colorectal cancer cells to anoikis. Cancer Letters. 2015;361:22–32. doi: 10.1016/j.canlet.2015.02.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2015.02.021</ArticleId>
            <ArticleId IdType="pubmed">25687885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan X, Tang B, Chen B, Shan Y, Yang H. Replication Study: the microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Elife. 2019;8:e43511.  doi: 10.7554/eLife.43511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.43511</ArticleId>
            <ArticleId IdType="pmc">PMC6414201</ArticleId>
            <ArticleId IdType="pubmed">30860027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang S, Wang H, Qin C, Sun H, Han Y. Up-regulation of CXCL8 expression is associated with a poor prognosis and enhances tumor cell malignant behaviors in liver cancer. Bioscience Reports. 2020;40:1–9. doi: 10.1042/BSR20201169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BSR20201169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang LY, Liu M, Li X, Tang H. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3) Journal of Biological Chemistry. 2013;288:4035–4047. doi: 10.1074/jbc.M112.410506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M112.410506</ArticleId>
            <ArticleId IdType="pmc">PMC3567655</ArticleId>
            <ArticleId IdType="pubmed">23212913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Q, Wu M, Zheng X, Yang L, Zhang Z, Li X, Chen J. ERGIC3 silencing additively enhances the growth inhibition of BFA on lung adenocarcinoma cells. Current Cancer Drug Targets. 2020;20:67–75. doi: 10.2174/1568009619666190917145906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1568009619666190917145906</ArticleId>
            <ArticleId IdType="pubmed">31530266</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
